

Evaluation of the Effect of Ascorbic Acid Administration on Gene Expression Level of IL-6 and TNF- α Cytokines in Deceased Donors

Masoumeh Kazemi^{1,2}, Seyed Mohammad Bagher Tabei^{2,3}, Katayoun Najafizadeh⁴,
Jafar Mehrabi Sisakht², Soheila Milani⁵, and Mohammad Bagher Khosravi⁵

¹ Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

² Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran

³ Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

⁴ Department of Pulmonary Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁵ Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Received: 18 April 2014; Received in revised form: 30 June 2014; Accepted: 13 July 2014

ABSTRACT

Brain death is associated with increased inflammatory cytokines levels and poor graft quality to transplant. We aimed to evaluate the impact of Ascorbic Acid (AA) on the inflammatory status of Brain-Dead Donors (BDDs).

Forty BDDs were randomly divided into two groups. Donor treatment (n=20) consisted of 100 mg/kg AA infusion 6 hours before donor operation and subsequent infusion of 100 mg/kg/p6h until organ removal. Blood samples were taken at three times, 6 hours before donor surgery (TP₁), immediately after laparotomy (TP₂), and before organ removal (TP₃). Gene expression level and serum concentration of IL-6 and TNF- α cytokines were assessed by real-time PCR and ELISA methods. To investigate transplanted liver function, serum values of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Billirubin-Total were evaluated on the 1st, 3rd, and 10th postoperative days.

We found a significant reduction in IL-6 mRNA expression ratio of TP₃ to TP₁ following AA application among BDDs. Despite the considerable decrease in treated donors regarding IL-6 mRNA expression ratio of TP₂ to TP₁, TP₃ to TP₂, and also TNF- α variations in these periods, the results were not significant. Regarding serum concentration of these cytokines, particularly IL-6, there was a decrease between TP₂ and TP₃ following AA application in the treated donors. Furthermore, a significant reduction was found in serum AST and ALT levels in the recipients of treated group on the 3rd day compared to the 1st day after transplantation.

It seems that AA beneficially affects the inflammatory status of BDDs, resulting in improved primary allograft function.

Keywords: Antioxidants; Ascorbic Acid; Brain death; Cytokines; Inflammation; Liver transplantation

Corresponding Author: Mohammad Bagher Khosravi, MD;
Anesthesiology and Critical Care Research Center, Shiraz

University of Medical Sciences, Namazee Hospital, Shiraz, Iran.
Tel/Fax: (+98 711) 6474 270, E-mail: khosravimb@sums.ac.ir

INTRODUCTION

Brain-dead patients are the main source of organ donation for transplantation.¹ Brain death, defined as an irreversible injury of the cerebrum, cerebellum, and brain stem, influences the donor graft quality by provoking hemodynamic, endocrinic, and immunologic changes.²⁻⁴ During the brain death process, a transient period of ischemia results in structural and functional changes in potential donor grafts^{5,6} so that the grafts derived from Brain-Dead Donors (BDD) trigger an increased inflammatory response, primary nonfunctioning, and acute rejection rates.^{7,8}

In many studies, cytokine system activation is the primary consequence of inflammation after brain death that mainly results from hemodynamic instability, hypoperfusion, and ischemia in various organs.^{9,10} The upregulation for the majority of pro-inflammatory cytokines was most obvious after laparotomy of the BDDs indicating the downstream summation of deleterious effects of various origins.¹ Important pro-inflammatory cytokines consist of IL-6, TNF- α , and IL-1 β , whereas IL-10 has anti-inflammatory effects.¹¹ It has been shown that the level of IL-6 was 5.6 times higher in brain dead patients compared to the living donors.¹ Higher donor IL-6 and TNF- α levels before organ procurement were associated with more post-operative complications and lower recipient survival after transplantation.^{12, 13}

Since brain death is a dynamic process rather than a constant situation, the time between the verification of brain death and organ removal could be an opportunity to perform the interventions that might attenuate the adverse consequences of brain death and ameliorate donor organ quality. In this way, it has been proved that the transplantation outcome closely depends on the quality of donor organs.^{14,15}

It is likely that the inflammatory response elicited by brain death could be due to hypoperfusion and ischemia. Peripheral ischemia is a strong inductor of pro-inflammation through the NF- κ B pathway.¹⁶ Since Reactive Oxygen Intermediates (ROI) appear to have important role in NF- κ B activation, inhibiting this step might be beneficial in limiting inflammation in certain clinical settings. In terms of NF- κ B inhibition, antioxidants are studied well. In this way Ascorbic Acid (AA), as an important physiological antioxidant, reverses the detrimental effects of ROI on the immune system and provokes immune homeostasis.¹⁷⁻²⁰ AA

quenches ROI involved in the activation of NF- κ B, acting as an antioxidant, AA donates two electrons and becomes oxidized to dehydroascorbic acid (DHA) which directly inhibits IKK α and IKK β enzymatic activity and subsequently down modulates NF- κ B signaling.^{21,22} It has been previously shown that the administration of 100 mg/kg AA intravenously attenuated the enhanced ischemia/reperfusion induced hepatic injury.²³ Therefore, this study aims to investigate the impact of AA on mRNA expression and serum level of IL-6 and TNF- α pro-inflammatory cytokines in peripheral blood mononuclear cells (PBMC) of the BDDs. We also aimed to determine if there were any possible effects on the primary allograft function following donor AA treatment.

PATIENTS AND METHODS

Patient Population and Sampling

This study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran. From April 2012 to March 2013, 40 brain deceased liver donors were prospectively randomized into 2 groups. The first group of the deceased donors received treatment with AA (n=20), while the second group remained without AA (Vitamin C) treatment (n=20). Randomization was performed using random numbers obtained by computer showing the sequence of recruited patients so that the odd numbers were allocated to the control group. Donor treatment consisted of 100 mg/kg AA (Daroupakhsh, Iran) infusion within 20 minutes, starting 6 hours before donor operation and thereafter 100 mg/kg/p6h i.v. continuously until organ removal.

All the deceased donors with infection and those who experienced cardiac arrest during admission or intensive care were excluded from the study. It should be mentioned that the researchers who did the experiments were blinded to the study.

Whole blood samples were obtained from the two groups of brain-dead liver donors and collected in K2-EDTA tubes (BD, UK). In both groups the samples were taken at three time points. The first sample was taken at 6 hours before donor operation (TP1), defining the baseline expression before AA administration. The second sample was taken immediately after donor laparotomy (TP2), before the start of donor surgery and further manipulations. The third sample was taken before organ removal at cross

clamp (TP3), reflecting the activation added by surgical manipulation.

Sample Preparation, RNA Extraction, and cDNA Synthesis

Peripheral blood was collected at the indicated time points, diluted in a 1:1 ratio with Phosphate Buffered Saline PBS (Inoclon, Iran), and centrifuged in Ficoll-Paque (Lymphodex, Germany) in a volume ratio of 1:2 (1 part ficoll to 2 part diluted blood) for 20 minutes at 2000 rpm and 25 °C. Then, the interface containing mononuclear cells (lymphocyte and monocytes) was collected and washed in PBS. RNA extraction was performed applying the QIAamp RNA Blood Mini Kit according to the manufacturer's instructions (QIAGEN, USA). Concentration and purity of extracted RNA were determined using NanoDrop ND-1000 (OD A260/A280 and A260/230) and integrity was confirmed by 2.0% agarose gel electrophoresis and visualizing of 28s and 18s rRNAs.

Total RNA was reverse-transcribed into cDNA using random hexamers and oligo-dT primers (Fermentase, Litvanya). Because various samples contained different amounts of RNA, the RNA concentration had to be standardized during the preparation of the reaction mixture by adjusting the volume of the RNA suspension based on the RNA concentration.

mRNA Expression Analysis of Cytokines

Gene expression was quantified using an ABI 5700 Real-Time PCR system (Applied Biosystem), applying SYBR Green master mix (Takara, Japan). The amplification took place in a two-step PCR (40 cycles; 20 seconds denaturation step [95 °C] and 34 seconds of annealing/extension step [60 °C]). To quantify the level of mRNA, we normalized the expression of the target

genes to the housekeeping gene GAPDH, and the data were expressed as the relative fold difference between cDNA of the study and the calibrator samples using pfaffl method.

Primer pairs of IL-6, TNF- α , and GAPDH were designed using the AlleleID 6 software in order to obtain the amplicons ranging from 80 and 150 bp. These primers were specifically designed to span exon/exon boundaries (Table 1). To confirm the amplification of the primers, the results (real-time PCR products) were visualized on 2.0% agarose gel (Cinnagen, Iran).

Determination of Serum IL-6 and TNF- α

Due to financial limitation, only in 12 patients from each group, in addition to the study of IL-6 and TNF- α cytokine gene expression at the mentioned time points, serum concentration of these cytokines were simultaneously determined. Computer generated random numbers were used to choose these donors. IL-6 and TNF- α concentrations were determined for each sample using ELISA kits (Bioassay Technology, China), by plotting the unknown samples against the calibration curve and by correcting for the dilution factor.

Clinical Parameters

To investigate whether AA administration to BDDs with immune system activation might have any protective influence on the transplanted liver function, we determined the serum level of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Billirubin-Total values as the parameters for liver function in every recipient of each group at three postoperative days (POD₁, POD₃, and POD₁₀).

Table 1. Primer sequences used for real-time PCR

| Genes | Primer sequences | Location | Product Size (bp) ^a |
|---------------|-----------------------------|----------|--------------------------------|
| GAPDH | F: TTGACCTCAACTACATGGTTTACA | F: 311 | 126 |
| | R: GCTCCTGGAAGATGGTGATG | R: 436 | |
| IL-6 | F: TGGATTCAATGAGGAGACTT | F: 428 | 81 |
| | R: TTCTGGAGGTACTCTAGGTATA | R: 508 | |
| TNF- α | F: AGCCTCTTCTCCTTCCTGAT | F: 269 | 142 |
| | R: AAGATGATCTGACTGCCTGG | R: 410 | |

^aAmplicon length in base pairs

Table 2. Characteristics of Ascorbic Acid treated and control brain-dead donors

| Variable | AA Treated (n=20) | Control (n=20) | P Value |
|--|-------------------|-------------------|---------|
| Donor Gender (Males:Females) | 60:40 | 80:20 | 0.3 |
| Donor Age, years (Means \pm SD) | 39 \pm 15.7 | 35 \pm 15.6 | 0.467 |
| Donor weight, kg (Means \pm SD) | 66.25 \pm 5.24 | 63.95 \pm 10.57 | 0.389 |
| Cause of brain death | | | |
| Aneurism/Subarachnoid hemorrhage | 4 | 6 | |
| Intracerebral hemorrhage | - | 1 | |
| Brain tumor | 3 | 2 | |
| Traumatic head injury due to car accident | 13 | 11 | |
| Time spent at ICU, hours (Means \pm SD) | 10.6 \pm 3 | 11.8 \pm 4.3 | 0.295 |
| Laboratory values, recent assessment (Mean \pm SD) | | | |
| AST, U/L | 78.55 \pm 54.55 | 84.45 \pm 61.67 | 0.75 |
| ALT, U/L | 45.25 \pm 28.43 | 59.6 \pm 39.14 | 0.193 |
| Bilirubin-total, mg/dl | 0.98 \pm 0.55 | 0.87 \pm 0.41 | 0.481 |
| Donor treatment | | | |
| Dopamine, μ g/kg/min (Mean \pm SD) | 6 \pm 2.6 | 6.8 \pm 2.9 | 0.399 |
| Methylprednisolone (mg) | 500 | 500 | 1 |

Statistical Analysis

Data are expressed as mean \pm SD in tables and presented as mean \pm SEM in figures. For single comparisons, normally distributed data were analyzed using independent samples T Test; non-normally distributed data were evaluated by nonparametric Mann-Whitney test. Categorical variables were compared using the chi square test. All the statistical analyses were performed using the SPSS statistical software, version 15.0 (SPSS, Chicago). $P < 0.05$ was considered statistically significant.

RESULTS

Donor Characteristics

Two donor groups were similar with respect to demographic and clinical characteristics (Table 2). Time to organ procurement after brain death was comparable between the two donor groups.

Recipient Characteristics

The study results revealed no statistically significant differences between 40 recipients of the graft from treated and untreated donors regarding age and gender parameters. Besides, the time for cold and warm ischemia and the primary etiology of liver disease were comparable between the two groups (Table 3).

Drug Application

The amount of applied fluids to both groups of

donors was comparable. The dosage of administrated steroid and catecholamine to the donors was almost equal in the two groups. There was no significant variation concerning the applied immunosuppressive regimen in donors and recipients. The mean of the total dosage of administered AA per donor was nearly 230 mg/kg which was infused within almost 8 hours. No complications were detected considering AA.

Cytokine mRNA Expression in Serial Blood Samples

To evaluate the impact of AA on the inflammatory status of the brain-dead liver donors, first we determined the gene expression level of IL-6 and TNF- α cytokines in the three mentioned time points (TP₁, TP₂, and TP₃). Then, we calculated the expression ratio of TP₂ to TP₁ ($R_{TP2:TP1}$), TP₃ to TP₁ ($R_{TP3:TP1}$), and TP₃ to TP₂ ($R_{TP3:TP2}$) for each gene per donor according to the pfafl method. At the end, we compared these results between the treated and untreated groups.

Our study results revealed a significant decrease in the amount of $R_{TP3:TP1}$ for IL-6 gene in the members of the treated donor group compared to the control group ($p=0.01$). Although AA application could affect the IL-6 expression ratio of TP₂ to TP₁ ($R_{TP2:TP1}$) and TP₃ to TP₂ ($R_{TP3:TP2}$), the results were not statistically significant ($p>0.05$). Regarding the analysis of TNF- α cytokine, in spite of the decrease in the three mentioned expression ratios in the treated donors, the difference was not statistically significant ($p>0.05$) (Figure 1).

Table 3. Characteristics of liver recipients from Ascorbic Acid (AA) treated and control brain-dead donors

| Variable | AA Treated (n=20) | Control (n=20) | P Value |
|--------------------------------------|-------------------|----------------|---------|
| Recipient Gender, % (M:F) | 60:40 | 50:50 | 0.75 |
| Recipient Age, years (mean±SD) | 37.4 ± 16 | 34.1 ± 14.2 | 0.489 |
| Etiology of end-stage liver diseases | | | |
| Hepatitis B virus | 6 | 4 | |
| Hepatitis C virus | 2 | 1 | |
| Primary sclerosing cholangitis | 1 | 3 | |
| Autoimmune hepatitis | 2 | 3 | |
| Wilson's disease | - | 1 | |
| Hypercholesterolemia | 2 | 1 | |
| Primary biliary cirrhosis | - | 2 | |
| Cryptogenic cirrhosis | 7 | 5 | |
| Cold Ischemia Time, min (mean± SD) | 203.2 ± 77.8 | 199.8 ± 71.6 | 0.883 |
| Warm Ischemia Time, min (mean± SD) | 38.8 ± 5.1 | 38 ± 5.5 | 0.657 |




Figure 1. Messenger RNA expression ratio of pro-inflammatory cytokines IL-6 and TNF- α at time point 2 to time point 1 (R TP2:TP1), time point 3 to time point 1 (R TP3:TP1), and time point 3 to time point 2 (R TP3:TP2) in the control and Ascorbic Acid (AA) treated brain-dead donors. The results are expressed as mean \pm SEM. (TP1: 6 hours before donor laparotomy, TP2: immediately after laparotomy, TP3: immediately before organ removal, * $p=0.01$).

Serum Level of Cytokines

Our investigation of the concentration of serum IL-6 and TNF- α cytokines revealed that AA administration could reduce these levels during the time between laparotomy and organ removal. Particularly, a significant decrease was observed in the amount of IL-6 at the TP₃ to the TP₂ in the AA treated group compared to the untreated one ($p=0.007$) (Figure 2).

Initial Transplanted Liver Function

Our study proved that both AST and ALT serum

parameters had decreased on the 3rd day to the 1st day after the operation in the patients receiving a graft from the treated donor group compared to the other group ($p<0.05$). Despite such a considerable reduction of these factors on the 10th day to the 1st day, no significant difference was found. Moreover, no significant difference was observed between the two groups of recipients regarding serum AST and ALT amount on the 10th day to the 3rd day and serum Billirubin-Total value in all the three mentioned comparisons (Figure 3).




Figure 2. Changes of IL-6 and TNF- α cytokine serum concentrations from time point 2 to time point 1 (TP₂₋₁), time point 3 to time point 1 (TP₃₋₁), and time point 3 to time point 2 (TP₃₋₂) in the Ascorbic Acid (AA) treated and control brain-dead donors. The results are expressed as mean \pm SEM. (TP₁: 6 hours before donor laparotomy, TP₂: immediately after laparotomy, TP₃: immediately before organ removal, * $p=0.007$).




Figure 3. Serum concentration of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and Billirubin-Total on the 3rd day to the 1st day (POD₃₋₁), the 10th day to the 3rd day (POD₁₀₋₃), and the 10th day to the 1st day (POD₁₀₋₁) after liver transplantation. The results are expressed as mean \pm SEM. (POD: Postoperative Day, * $p=0.023$, ** $p=0.043$).

DISCUSSION

This study was conducted to evaluate the potential influence of AA on gene expression level of IL-6 and TNF- α cytokines in brain-dead liver donors who had undergone up-regulation of these pro-inflammatory

cytokines. Based on our results, AA appears to exert a modulatory effect on the inflammatory status of the brain-dead donors by attenuating the expression level of these genes. We also found that AA application might have a protective impact on the primary function of the transplanted liver.

Brain death is considered to be an important alloantigen independent risk factor in transplantation.^{8,24} As it is associated with a rapid up-regulation of the inflammatory mediators and subsequently with mononuclear cell infiltration in end organs,²⁵⁻²⁷ it thus seems that the allografts obtained from BDDs are more immunogenic compared to the grafts obtained from the living donors.²⁸

A major consequence of brain death is the occurrence of hypotension which can subsequently cause organ hypoperfusion and ischemia. The resulted ischemia then promotes the generation of ROI²⁹ that can induce the activation of NF- κ B transcription factor. This in turn leads to up-regulation of pro-inflammatory cytokine mRNA expression, like IL-6 and TNF- α . Therefore, antioxidant mechanisms seem to be useful in preventing the NF- κ B activation.^{17,30} On the basis of this information, we evaluated the effect of AA treatment on ameliorating the inflammatory status of BDDs.

Our findings showed that AA application reduced the mRNA expression level of IL-6 mainly before organ removal. Although the TNF- α mRNA content in the studied PBMCs was affected by AA treatment, the result was not statistically significant. To determine whether the results of gene expression were comparable with the protein levels, we also conducted serum measurement of IL-6 and TNF- α cytokines at the three mentioned time points. In accordance with the consequent changes in mRNA expression ratio, similar changes were observed in the serum concentration of these factors; we found a significant decrease in the serum level of IL-6 at TP₃ to TP₂ following AA treatment. Here, the point to be noted is the sequence of the changes which occurred in mRNA expression and protein translation levels. It is expected that we have the peak of mRNA level before the peak of proteins. Hence, this finding can be confirmed although it would have been better to include a larger sample size for this confirmation. Furthermore, our study results revealed that BDD treatment with AA showed a beneficial influence on the function of the transplanted liver. Besides, it was shown that the serum level of AST and ALT were less in the recipients of the treated donors compared to the control group on the 3rd day after the surgery. However, no such protective effect was found regarding the Billirubin-Total value.

Our finding on the anti-inflammatory effects of AA seem to be in concordance with those of the previous

researches. A recent study by Lu et al.³¹ provided evidence that AA intake (100 mg/kg for 15 days) in rats significantly lowered the plasma level of TNF- α , IL-1 β , and IL-6 following diquat induced oxidative stress. In another in vitro study, it was reported that AA selectively influenced the production of intracytoplasmic IL-6 and TNF- α cytokines in monocytes and lymphocytes.³² Also it was reported that AA could diminish the nicotin-induced enhanced TNF- α and IL-12 cytokine release and mRNA levels.³³

Although the precise mechanism behind the immunomodulatory effect of AA is not indentified, it is tempting to postulate that this effect is largely mediated by antioxidant properties of AA. Therefore, inhibition of NF- κ B activation due to the antioxidantcy of AA is a plausible explanation for this issue. Excess of ROI in ascorbate depleted cells leads to activation of IKK β , dissociation of NF- κ B/I- κ B transcriptional complexes, nuclear translocation, and subsequent NF- κ B dependent gene expression. AA quenches ROI and inhibits IKK β activating.^{22,34} It has also been proposed that AA, when oxidizes to Dihydro Ascorbic Acid (DHA) form, can act as a kinase inhibitor, which directly inhibits the activation of IKK β and IKK α , and subsequently modulate the ROI dependent NF- κ B signaling.^{22,35}

Results of this study might be interpreted in light of possible limitations. Since we had the peak of AA influence at the last time point (before organ removal), it seems better to start the intervention at a time earlier than we did (for example at the time of confirming the brain death diagnosis or at the time of consent for organ donation) to have a prolonged treatment period. Moreover, our applied amount of AA might have been insufficient. Therefore, it seems possible for AA to affect the immunogenicity of BDD and exert an improved graft function after transplantation.

Our experiment revealed that AA administration showed modulatory effects on the pro-inflammatory cytokine levels, particularly down-regulating the mRNA of IL-6. We also found that AA treatment resulted in an improvement in the primary graft function compared to the non-treated group. Nonetheless, further studies are still needed to establish this impact of AA.

ACKNOWLEDGEMENTS

This study was supported by grants from Vice Chancellor for Research and Student Research

Committee, Shiraz University of Medical Sciences, Shiraz, Iran. The authors would like to thank Ms. Roosta for statistical analysis at Center for Development of Clinical Research of Nemazee Hospital. This article was extracted from the thesis written by Masoumeh Kazemi. The authors declare that they have no competing interests.

REFERENCES

1. Weiss S, Kotsch K, Francuski M, Reutzel-Selke A, Mantouvalou L, Klemz R, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. *Am J Transplant* 2007; 7(6):1584-93.
2. Chen EP, Bittner HB, Kendall SW, Van Trigt P, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. *Crit Care Med* 1996; 24(8):1352-9.
3. Pratschke J, Wilhelm MJ, Kusaka M, Basker M, Cooper DK, Hancock WW, et al. Brain death and its influence on donor organ quality and outcome after transplantation. *Transplantation* 1999; 67(3):343-8.
4. Nicholas T. Transplantation biology: Cellular and molecular aspects. 1st ed. Lippincott Williams & Wilkins ; 1996
5. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. *Transplantation* 1988; 45(1):32-6.
6. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. *Transplantation* 2003; 75(12):1928-33.
7. Wilhelm MJ, Pratschke J, Beato F, Taal M, Kusaka M, Hancock WW, et al. Activation of the Heart by Donor Brain Death Accelerates Acute Rejection After Transplantation. *Circulation* 2000; 102(19):2426-33.
8. Pratschke J, Wilhelm MJ, Kusaka M, Beato F, Milford EL, Hancock WW, et al. Accelerated rejection of renal allografts from brain-dead donors. *Ann Surg* 2000; 232(2):263-71.
9. Ott L, McClain CJ, Gillespie M, Young B. Cytokines and metabolic dysfunction after severe head injury. *J Neurotrauma* 1994; 11(5):447-72.
10. Bugge JF. Brain death and its implications for management of the potential organ donor. *Acta Anaesthesiol Scand* 2009; 53(10):1239-50.
11. Barklin A. Systemic inflammation in the brain-dead organ donor. *Acta Anaesthesiol Scand* 2009; 53(4):425-35.
12. Murugan R, Venkataraman R, Wahed AS, Elder M, Hergenroeder G, Carter M, et al. Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation. *Crit Care Med* 2008; 36(6):1810-6.
13. Azarpira N, Nikeghbalian S, Kazemi K, Geramizadeh B, Malekpour Z, Malek-Hosseini SA. Association of Increased Plasma Interleukin-6 and TNF- α Levels in Donors with the Complication Rates in Liver Transplant Recipients. *Int J Organ Transplant Med* 2013; 4(1):9-14.
14. Zhang SJ, Wang T. The influence of brain death on donor liver and the potential mechanisms of protective intervention. *Front Med* 2011; 5(1):8-14.
15. Martins PN, Chandraker A, Tullius SG. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. *Transpl Int* 2006; 19(5):351-9.
16. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annu Rev Immunol*. 1996; 14:649-83.
17. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. *Intensive Care Med* 1998; 24(11):1131-8.
18. Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, et al. Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy. *J Transl Med* 2014; 12(1):127.
19. Kelley DS, Bendich A. Essential nutrients and immunologic functions. *Am J Clin Nutr* 1996; 63(6):994S-996S.
20. Jacob RA, Burri BJ. Oxidative damage and defense. *Am J Clin Nutr* 1996; 63(6):985S-990S.
21. Mandl J, Szarka A, Banhegyi G. Vitamin C: update on physiology and pharmacology. *Brit J Pharmacol* 2009; 157(7):1097-110.
22. Carcamo JM, Pedraza A, Borquez-Ojeda O, Zhang B, Sanchez R, Golde DW. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits I κ B α Kinase β . *Mol Cell Biol* 2004; 24:6645-52.
23. Seo MY, Lee SM. Protective effect of low dose of ascorbic acid on hepatobiliary function in hepatic ischemia/reperfusion in rats. *J Hepatol* 2002; 36(1):72-7.
24. Tullius SG, Heemann UW, Azuma H, Hancock WW, Tilne NL. Alloantigen-independent factors lead to signs of chronic rejection in long-term kidney isografts. *Transpl Int* 1994; 7(Suppl 1):306-7.

25. Jassem W, Koo DD, Cerundolo L, Rela M, Heaton ND, Fuggle SV. Cadaveric versus living-donor livers: differences in inflammatory markers after transplantation. *Transplantation* 2003; 76(11):1599-603.
26. Jassem W, Koo DD, Cerundolo L, Rela M, Heaton ND, Fuggle SV. Leukocyte infiltration and inflammatory antigen expression in cadaveric and living-donor livers before transplant. *Transplantation* 2003; 75(12):2001-7
27. Van der Hoeven JA, Ploeg RJ, Postema F, Molema I, de Vos P, Girbes AR, et al. Induction of organ dysfunction and up-regulation of inflammatory markers in the liver and kidneys of hypotensive brain dead rats: a model to study marginal organ donors. *Transplantation* 1999; 68(12):1884-90.
28. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med* 1995; 333(6):333-6.
29. Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Plets C, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. *Circulation* 1993; 87(1):230-9.
30. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. *J Clin Invest* 2001; 107(1):7-11.
31. Lu T, Piao X, Zhang Q, Wang D, Piao X, Kim S. Protective effects of *Forsythia suspensa* extract against oxidative stress induced by diquat in rats. *Food Chem Toxicol* 2010; 48(2):764-70
32. Hartel C, Strunk T, Bucsky P, Schultz C. Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. *Cytokine* 2004; 27(4-5):101-6.
33. Mahapatra SK, Chakraborty SP, Roy S. Immunomodulatory role of *Ocimum gratissimum* and ascorbic acid against nicotine-induced murine peritoneal macrophages in vitro. *Oxid Med Cell Longev* 2011; 2011:734319.
34. Schwager J, Schulze J. Modulation of interleukin production by ascorbic acid. *Vet Immunol Immunopathol* 1998; 64(1):45-57.
35. Carcamo JM, Pedraza A, Bórquez-Ojeda O, Golde DW. Vitamin C suppresses TNF α -induced NF κ B activation by inhibiting I κ B α phosphorylation. *Biochemistry* 2002; 41(43):12995-3002.

Archive of SID